XML 61 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 11, 2018
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Dec. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Revenues                     $ 2,502,624 $ 2,000,868 $ 24,448,761 $ 1,529,644 $ 8,787,234 $ 2,644,543 $ 20,412,124 $ 10,376,185   $ 30,481,897 $ 42,220,086 $ 35,368,361
Revenue recognized from deferred revenue beginning balance                                       1,300,000 14,800,000  
Deferred grant funding       $ 4,165,848   $ 0         4,165,848       0         4,165,848 0  
ApolloBio                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Revenues                                       23,000,000    
ApolloBio | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Territory expansion option period   3 years                                        
Proceeds from collaborative agreement         $ 19,400,000                                  
Upfront payment received         23,000,000                             $ 23,000,000    
Collaborative agreement, advisory fees         960,000                 $ 960,000                
Additional revenue to be achieved                                     $ 20,000,000      
Obligation period to pay royalties                                       10 years    
Collaborative agreement, period from effective date for termination                                       1 year    
Collaborative agreement, number of days written notice before termination                                       90 days    
AstraZeneca                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Revenues                                       $ 6,900,000    
Revenues                                         22,300,000  
AstraZeneca | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Upfront payment received               $ 27,500,000                         27,500,000  
Collaboration agreement, anticipated development and regulatory event based payment receivable milestones                                       355,000,000    
Collaboration agreement, anticipated commercial event based payment receivable milestones                                       345,000,000    
Number of additional products | product     2                                      
Collaborative agreement, milestone payment, revenue recognized       2,000,000   7,000,000                                
Deferred revenue       288,000   1,100,000         288,000       1,100,000         288,000 1,100,000  
Accounts receivable       3,200,000   1,700,000         3,200,000       1,700,000         3,200,000 1,700,000  
Roche | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Upfront payment received                   $ 10,000,000                        
Full payment             $ 8,500,000                              
Revenue recognized from deferred revenue beginning balance                                       0    
Revenue under collaborative research and development arrangements                                         6,100,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Upfront payment received                                       6,500,000    
Collaborative agreement, funding to be received $ 56,000,000                                          
Collaborative agreement, period to receive funding for research and development 5 years                                          
Collaborative agreement, funding received                                       4,300,000    
Deferred grant funding       2,100,000             2,100,000                 2,100,000    
DARPA | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Deferred revenue       74,000   149,000         74,000       149,000         74,000 149,000  
Accounts receivable       $ 82,000   $ 4,100,000         $ 82,000       $ 4,100,000         82,000 4,100,000  
Collaborative agreement, funding received                                       $ 1,100,000 $ 9,800,000  
Base award                 $ 19,600,000                          
Option award                 $ 24,600,000                          
Foreign Tax Authority | ApolloBio | Collaborative Arrangement, Product                                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                            
Collaborative agreement, corporate income tax         2,200,000                                  
Collaborative agreement, foreign non-income Taxes         $ 1,400,000